Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...

In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: Astrazeneca. Legal News and Analysis - China - Conventus Law ...

For years, GoPro was synonymous with action cameras, but in 2025 the market looks a little different. GoPro still makes some of the best action cameras, including its latest flagship the GoPro ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent ...

SGLT-2 inhibitors, initially developed for type 2 diabetes, demonstrate profound cardiorenal and metabolic benefits. This review synthesizes evidence from clinical trials and mechanistic studies to ...

Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) is a dual-action therapy combining an SGLT2 inhibitor with a DPP4 inhibitor for more effective management of T2DM with cardio renal risks.

ABSTRACT: Background: Euglycemic Diabetic Ketoacidosis (EDKA) is a rare but well-known adverse effect of sodium glucose transporter 2 (SGLT-2) inhibitors. This class of antidiabetic medications has ...